Mesh Bio has raised US$3.5 million in Series A financing led by East Ventures, a pioneering and leading sector-agnostic venture capital firm focusing on Southeast Asia.

Mesh Bio Attains Regulatory Approval for HealthVector® Diabetes, a Digital Twin Technology Capable of Predicting 3-year Onset Risk of Chronic Kidney Disease in Diabetes Patients HealthVector® Diabetes to be piloted at select polyclinics and Singapore General Hospital (SGH) and Tan Tock Seng Hospital (TTSH) for potential clinical adoption, following the award of the National Health Innovation Centre (NHIC) Innovation to Adopt (I2Adopt) Grant to both hospitals

Mesh Bio raises funding from East Ventures, a pioneering and leading sector-agnostic venture capital firm focusing on Southeast Asia.

The partnership will see the adoption of Mesh Bio’s predictive analytics software to advance diagnostic services across more than 30 centres in Indonesia by PT Pramita. Mesh Bio’s proprietary software will be able to deliver personalised preventive care and disease risk by providing actionable health insights for each patient.

Singapore-based Mesh Bio, a digital health startup transforming chronic disease management through predictive analytics, and UK-based artificial intelligence (AI)-enabled drug discovery company MultiOmic Health today announce their partnership to conduct an observational clinical study on patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease.

Singapore-based healthtech startup Mesh Bio has raised USD1.8 million (SGD2.4 million) in Seed funding, led by deep tech investors Elev8.vc and Enterprise Singapore’s investment arm Seeds Capital, along with Citrine Capital and Tael Partners. The funds will be used to accelerate the rollout of Mesh Bio’s solution, DARA® – a predictive analytics and clinical workflow automation solution for healthcare providers – in Southeast Asia and Hong Kong. The funding will also support clinical partnerships and collaborations.

Mesh Bio, a Singapore-based predictive analytics digital health startup for diagnosis and management of chronic diseases, has announced today their participation in the upcoming Startup Creasphere Batch 3 accelerator program, an international collaboration set to pilot Mesh Bio’s digital solutions.

Mesh Bio has been selected to showcase our innovative chronic disease management solutions at this event. SHBC is National Healthcare Group’s annual flagship event and has established itself as Singapore’s leading healthcare congress.

Mesh Bio exhibiting in HIMSS 2023. HIMSS is the premier global health information and technology event, presenting the opportunity for attendees and exhibitors to inspire, innovate and network with the goal of advancing healthcare systems.